VWV have supported longstanding client, the University of Bristol, in relation to Artificial Intelligence Research Resource hosted by the University known as "Isambard-AI".
For UK Life Sciences, the MHRA shoulders the responsibility for balancing between making the UK a hub for AI innovation, and keeping products within acceptable limits. A likely rise in AI-related medical products also adds to the challenge.
Using BenevolentAI's AI-driven drug discovery platform, the two companies have jointly identified a novel target for heart failure, which has been added to AstraZeneca’s discovery portfolio.
Several years in the making, The National Health Service (General Medical Services - Premises Costs) Directions 2024 (The 2024 Directions) were published on 9 May 2024.